VAXCYTE, INC. Operating Expenses
VAXCYTE, INC. (PCVX) reported Operating Expenses of $302.78 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-05
- VAXCYTE, INC. operating expenses for the quarter ending 2026-06-30 was $302.78M, a 33.84% increase year-over-year.
- VAXCYTE, INC. operating expenses for the quarter ending 2026-03-31 was $345.85M, a 91.30% increase year-over-year.
- VAXCYTE, INC. operating expenses for the quarter ending 2025-12-31 was $274.28M, a 69.13% increase year-over-year.
- VAXCYTE, INC. operating expenses for the quarter ending 2025-09-30 was $242.38M, a 73.22% increase year-over-year.
- VAXCYTE, INC. operating expenses for fiscal 2025 was $923.67M, a 62.18% increase from fiscal 2024.
- VAXCYTE, INC. operating expenses for fiscal 2024 was $569.55M, a 21.69% increase from fiscal 2023.
- VAXCYTE, INC. operating expenses for fiscal 2023 was $468.04M, a 101.52% increase from fiscal 2022.
- VAXCYTE, INC. operating expenses for fiscal 2022 was $232.26M, a 124.03% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $302.78M 10-Q · filed 2026-08-05 | $648.63M 10-Q · filed 2026-08-05 | $922.91M derived: sum of 3 quarters · filed 2026-08-05 | $1.17B derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $345.85M 10-Q · filed 2026-05-06 | $620.13M derived: sum of 2 quarters · filed 2026-05-06 | $862.51M derived: sum of 3 quarters · filed 2026-05-06 | $1.09B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $274.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $516.66M derived: sum of 2 quarters · filed 2026-02-24 | $742.88M derived: sum of 3 quarters · filed 2026-08-05 | $923.67M 10-K · filed 2026-02-24 |
| 2025-09-30 | $242.38M 10-Q · filed 2025-11-04 | $468.60M derived: sum of 2 quarters · filed 2026-08-05 | $649.39M 10-Q · filed 2025-11-04 | $811.56M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $226.22M 10-Q · filed 2026-08-05 | $407.01M 10-Q · filed 2026-08-05 | $569.18M derived: sum of 3 quarters · filed 2026-08-05 | $709.11M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $180.79M 10-Q · filed 2026-05-06 | $342.96M derived: sum of 2 quarters · filed 2026-05-06 | $482.89M derived: sum of 3 quarters · filed 2026-05-06 | $635.87M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $162.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $302.09M derived: sum of 2 quarters · filed 2026-02-24 | $455.07M derived: sum of 3 quarters · filed 2026-02-24 | $569.55M 10-K · filed 2026-02-24 |
| 2024-09-30 | $139.92M 10-Q · filed 2025-11-04 | $292.90M derived: sum of 2 quarters · filed 2025-11-04 | $407.38M 10-Q · filed 2025-11-04 | $604.05M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $152.98M 10-Q · filed 2025-08-06 | $267.45M 10-Q · filed 2025-08-06 | $464.13M derived: sum of 3 quarters · filed 2026-02-24 | $577.15M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $114.47M 10-Q · filed 2025-05-07 | $311.15M derived: sum of 2 quarters · filed 2026-02-24 | $424.17M derived: sum of 3 quarters · filed 2026-02-24 | $511.32M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $196.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $309.70M derived: sum of 2 quarters · filed 2026-02-24 | $396.85M derived: sum of 3 quarters · filed 2026-02-24 | $468.04M 10-K · filed 2026-02-24 |
| 2023-09-30 | $113.03M 10-Q · filed 2024-11-05 | $200.17M derived: sum of 2 quarters · filed 2024-11-05 | $271.37M 10-Q · filed 2024-11-05 | $357.94M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $87.15M 10-Q · filed 2024-08-06 | $158.34M 10-Q · filed 2024-08-06 | $244.91M derived: sum of 3 quarters · filed 2025-02-25 | $303.49M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $71.19M 10-Q · filed 2024-05-08 | $157.76M derived: sum of 2 quarters · filed 2025-02-25 | $216.34M derived: sum of 3 quarters · filed 2025-02-25 | $264.23M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $86.57M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $145.15M derived: sum of 2 quarters · filed 2025-02-25 | $193.04M derived: sum of 3 quarters · filed 2025-02-25 | $232.26M 10-K · filed 2025-02-25 |
| 2022-09-30 | $58.58M 10-Q · filed 2023-11-06 | $106.46M derived: sum of 2 quarters · filed 2023-11-06 | $145.68M 10-Q · filed 2023-11-06 | $175.53M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $47.89M 10-Q · filed 2023-08-08 | $87.11M 10-Q · filed 2023-08-08 | $116.95M derived: sum of 3 quarters · filed 2024-02-27 | $143.90M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $39.22M 10-Q · filed 2023-05-08 | $69.07M derived: sum of 2 quarters · filed 2024-02-27 | $96.02M derived: sum of 3 quarters · filed 2024-02-27 | $119.75M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $29.85M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $56.80M derived: sum of 2 quarters · filed 2024-02-27 | $80.53M derived: sum of 3 quarters · filed 2024-02-27 | $103.67M 10-K · filed 2024-02-27 |
| 2021-09-30 | $26.95M 10-Q · filed 2022-11-07 | $50.68M derived: sum of 2 quarters · filed 2022-11-07 | $73.82M 10-Q · filed 2022-11-07 | $93.28M derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | $23.73M 10-Q · filed 2022-08-08 | $46.87M 10-Q · filed 2022-08-08 | $66.33M derived: sum of 3 quarters · filed 2022-08-08 | $87.63M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $23.14M 10-Q · filed 2022-05-09 | $42.60M derived: sum of 2 quarters · filed 2022-05-09 | $63.90M derived: sum of 3 quarters · filed 2022-05-09 | $85.13M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $19.45M 10-K · filed 2021-03-29 | $40.76M derived: sum of 2 quarters · filed 2021-11-10 | $61.98M derived: sum of 3 quarters · filed 2021-11-10 | $89.58M 10-K · filed 2023-02-27 |
| 2020-09-30 | $21.31M 10-Q · filed 2021-11-10 | $42.53M derived: sum of 2 quarters · filed 2021-11-10 | $70.13M 10-Q · filed 2021-11-10 | $85.97M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $21.22M 10-Q · filed 2021-08-11 | $48.82M 10-Q · filed 2021-08-11 | $64.66M derived: sum of 3 quarters · filed 2021-08-11 | $76.80M derived: sum of 4 quarters · filed 2021-08-11 |
| 2020-03-31 | $27.60M 10-Q · filed 2021-05-11 | $43.43M derived: sum of 2 quarters · filed 2021-05-11 | $55.57M derived: sum of 3 quarters · filed 2021-05-11 | $67.81M derived: sum of 4 quarters · filed 2021-05-11 |
| 2019-12-31 | $15.84M 10-K · filed 2021-03-29 | $27.98M derived: sum of 2 quarters · filed 2021-03-29 | $40.21M derived: sum of 3 quarters · filed 2021-03-29 | $54.15M 10-K · filed 2022-02-28 |
| 2019-09-30 | $12.14M 10-K · filed 2021-03-29 | $24.37M derived: sum of 2 quarters · filed 2021-03-29 | $38.31M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $12.23M 10-K · filed 2021-03-29 | $26.18M 10-Q · filed 2020-08-12 | ||
| 2019-03-31 | $13.94M 10-K · filed 2021-03-29 | |||
| 2018-12-31 | $35.53M 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |